The Onychomycosis (Tinea Unguium) drugs in development market research report provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Onychomycosis (Tinea Unguium). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued products.

GlobalData tracks 16 drugs in development for Onychomycosis (Tinea Unguium) by 17 companies/universities/institutes. The top development phase for Onychomycosis (Tinea Unguium) is phase ii with six drugs in that stage. The Onychomycosis (Tinea Unguium) pipeline has 15 drugs in development by companies and one by universities/ institutes. Some of the companies in the Onychomycosis (Tinea Unguium) pipeline products market are: Blueberry Therapeutics, Mycovia Pharmaceuticals and Moberg Pharma.

The key targets in the Onychomycosis (Tinea Unguium) pipeline products market include Squalene Monooxygenase (Squalene Epoxidase or SQLE or EC 1.14.14.17), Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC 1.14.14.154), and Cell Membrane.

The key mechanisms of action in the Onychomycosis (Tinea Unguium) pipeline product include Squalene Monooxygenase (Squalene Epoxidase or SQLE or EC 1.14.14.17) Inhibitor with four drugs in Phase III. The Onychomycosis (Tinea Unguium) pipeline products include four routes of administration with the top ROA being Topical and one key molecule types in the Onychomycosis (Tinea Unguium) pipeline products market including Small Molecule.

Onychomycosis (Tinea Unguium) overview

Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail, and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.

For a complete picture of Onychomycosis (Tinea Unguium)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.